333 related articles for article (PubMed ID: 29735843)
1.
Pragsam AK; Kumar DT; Doss CGP; Iyadurai R; Satyendra S; Rodrigues C; Joshi S; Roy I; Chaudhuri BN; Chitnis DS; Tapan D; Veeraraghavan B
Indian J Med Microbiol; 2018; 36(1):127-130. PubMed ID: 29735843
[TBL] [Abstract][Full Text] [Related]
2. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Grupper M; Sutherland C; Nicolau DP
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
[TBL] [Abstract][Full Text] [Related]
4.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
Shortridge D; Pfaller MA; Castanheira M; Flamm RK
Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
[TBL] [Abstract][Full Text] [Related]
7. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
Pfaller MA; Bassetti M; Duncan LR; Castanheira M
J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
Seifert H; Körber-Irrgang B; Kresken M;
Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
[TBL] [Abstract][Full Text] [Related]
9. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
10. Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections.
Patankar M; Sukumaran S; Chhibba A; Nayak U; Sequeira L
J Assoc Physicians India; 2012 Nov; 60():22-4. PubMed ID: 23767198
[TBL] [Abstract][Full Text] [Related]
11. Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.
MacVane SH; Pandey R; Steed LL; Kreiswirth BN; Chen L
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947473
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Tato M; García-Castillo M; Bofarull AM; Cantón R;
Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
[TBL] [Abstract][Full Text] [Related]
13. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Henderson A; Tan E; McCarthy KL; Paterson DL
Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
[TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
Finklea JD; Hollaway R; Lowe K; Lee F; Le J; Jain R
Diagn Microbiol Infect Dis; 2018 Sep; 92(1):75-77. PubMed ID: 29884565
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.
Sutherland CA; Nicolau DP
Clin Ther; 2015 Jul; 37(7):1564-71. PubMed ID: 26088525
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
Xipell M; Bodro M; Marco F; Martínez JA; Soriano A
Future Microbiol; 2017 Nov; 12():1323-1326. PubMed ID: 28980834
[TBL] [Abstract][Full Text] [Related]
17. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Flamm RK; Castanheira M
J Glob Antimicrob Resist; 2017 Sep; 10():186-194. PubMed ID: 28735046
[TBL] [Abstract][Full Text] [Related]
18. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Cho JC; Fiorenza MA; Estrada SJ
Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
[TBL] [Abstract][Full Text] [Related]
19. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
Vickery SB; McClain D; Wargo KA
Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
[TBL] [Abstract][Full Text] [Related]
20. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
Wi YM; Greenwood-Quaintance KE; Schuetz AN; Ko KS; Peck KR; Song JH; Patel R
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29133568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
